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An extensive study was carried out on HSA and non-enzymatically glycated HSA by
enzymatic digestion with trypsin and endoproteinase Lys-C, with the aim of identifying
specific glycated peptides deriving from enzymatic digestion of glycated HSA. They may be
considered, in pectore, as advanced glycation end products/peptides. These compounds,
important at a systemic level in diabetic and nephropathic subjects, are produced by enzymatic
digestion of in vivo glycated proteins: They are related to the pathological state of patients and
have been invoked as responsible for tissue modifications. The digested mixtures obtained by
the two enzymes were analyzed by MALDI/MS and LC/ESI/MSn, and clear cut differences
were found. First of all, the digestion products of glycated HSA are generally less abundant
than those observed in the case of unglycated HSA, accounting for the lower proclivity of the
former to enzymatic digestion. MS/MS experiments on doubly charged ions, comparisons
with a protein database, and molecular modeling to identify the lysine NH2 groups most
exposed to glycation, identified some glycated peptides in digestion mixtures obtained from
both types of enzymatic digestion. Residues 233K, 276K, 378K, 545K, and 525K seem to be
privileged glycation sites, in agreement with the fractional solvent accessible surface values
calculated by molecular modeling. (J Am Soc Mass Spectrom 2004, 15, 496–509) © 2004
American Society for Mass SpectrometryDiabetes is a widespread disease, involving about4% of the entire world population. For thisreason, many efforts have been devoted to the
wide application of valid monitoring procedures and to
the development of effective therapeutic approaches.
Although these efforts have led to reduced mortality,
mainly related to optimized control of the acute com-
plications of the disease (hypoglycemic coma, ketoaci-
dosis, infections), the long-term complications of diabe-
tes (macroangiopathy, nephropathy, retinopathy,
neuropathy) still remain widespread and constitute a
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The first effect of the high glucose concentration in
biological fluids, typical of diabetes, is non-enzymatic
protein glycation. When a protein undergoes high glu-
cose concentration, a reaction between either terminal
or lysine- amino groups and glucose takes place. This
reaction, originally studied by Maillard [1, 2], leads to
the production of glycated proteins which, to some
extent, can release the chemically modified sugar moi-
ety, leading to the formation of highly reactive species
called “Advanced Glycation End Products” (AGE) [3].
In turn, AGE can react with other proteins, leading to
chemically altered species which can activate cross-
linking reactions [4]. These reactive species can also
interact at the cellular level with specific receptorsr Inc. Received July 31, 2003
Revised October 17, 2003
Accepted November 19, 2003
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flammatory reactions reflected in tissue damage [5].
These chemical pathways can be invoked to explain the
tissue modifications typical of long-term diabetic com-
plications [6].
High circulating AGE levels are due either to their
high production (as in diabetes) or to impaired kidney
excretion (as in chronic renal failure) [7].
Hence, high AGE concentrations reflect the produc-
tion of AGE-modified proteins which, being chemically
altered, show different biological activity, activating a
macrophage response with consequent internalization
and digestion [8]. AGE-modified proteins can then
generate a series of AGE-modified and highly reactive
peptides, which react with plasma lipoprotein (low-
density lipoprotein, LDL) to form AGE-modified LDL
and cross-links with collagen. Thus, AGE peptides
exhibit the same toxic activity as AGEs and, conse-
quently, are invoked as responsible for the tissue mod-
ifications typical of complications of diabetes and
chronic renal failure [9].
Studies on AGE peptides are consequently of great
interest and lead to the identification of chemical spe-
cies related to patients’ pathological conditions. Their
identification must necessarily be considered from the
structural point of view because, once their structures
have been defined, their origin can also be defined and
pharmacological approaches can be designed.
In view of the great complexity of plasma, direct
identification of AGE peptides in this substrate is cer-
tainly a difficult task. Consequently, it was believed of
interest to start from some in vitro experiments, based
on in vitro non-enzymatic glycation of proteins of
known structure, followed by their enzymatic diges-
tion.
The analytical approach used in early researches in
this framework mainly applied liquid chromatography
[10]. Clearcut differences were found between the di-
gestion mixtures of glycated and unglycated proteins
but no structural information on the species present in
the case of glycated proteins could be obtained. Highly
specific techniques are required and thus mass spectro-
metry, particularly the latest techniques devoted to
proteome, seemed to be suitable. In a first application of
this approach, bovine serum albumin (BSA) was gly-
cated in vitro, following Gugliucci and Bendayan [10]
and digested by proteinase K [11]. The digestion mix-
ture was very complex due to the high enzymatic
activity. Comparisons of LC/ESI/MS chromatograms
of digested samples from glycated and unglycated
proteins revealed definite differences and the molecular
weights of some species only present in glycated BSA
were easily determined. Some structural information
was gained from MS/MS experiments but, due to the
extensive action of the enzyme, no definitive structural
results were obtained.
For more specific results, in a further study [12]
human serum albumin (HSA) was glycated in vitro and
a more specific enzyme was employed for its digestion.LC/ESI/FTMS was also used as analytical approach,
identifying about 20 glycated peptides. Their structures
were postulated on the basis of accurate mass measure-
ments and on the known sequence of HSA [13]. Inter-
estingly, some cross-linking products were identified
among them, indicating the occurrence of intra-molec-
ular cross-links. Another point highlighted in that study
was the yield of digestion products of glycated HSA,
which was lower than that observed in unglycated
protein. This fits the medical hypothesis, i.e., that gly-
cated proteins are more difficult to digest enzymatically
and consequently accumulate at a systemic level.
For further structural information, we undertook the
present study, based on two different types of enzy-
matic digestion, i.e., trypsin and endoproteinase Lys-C
(Lys-C) of glycated HSA, and on comparisons with the
digestion products of unglycated protein. In order to
obtain information on the preferential glycation sites of
the protein, LC/ESI/MSn experiments were performed
on doubly charged ions and the resulting data were
compared with those from theoretical calculations.
Experimental
All reagents and solvents were used as purchased
without further purification.
Glycation of HAS
In vitro glycation of pure, defatted HSA was carried out
with glucose, according to a published procedure [12].
Briefly, HSA (Sigma, St Louis, MO) [100 mg/mL
(1.5103 M) in 0.01 M phosphate buffer (Carlo Erba
Reagenti, Rodano, Italy), pH 7.4, containing 5 mM
toluene (Carlo Erba Reagenti) as a bacteriostatic] was
incubated with 0.5 M D-glucose (Sigma, St Louis) at
37 °C for 28 days. After incubation, the HSA was
separated from the solution by centrifugation through a
Centricon-50 membrane (Millipore Corporation, Bed-
ford, MA; MW cut-off 50,000 Da) at 5000  g for 1 h,
dialyzed extensively against distilled water (MW cut-
off 50,000, Spectrum Laboratories) and then lyophilized.
Unglycated HSA was incubated in the same conditions
without the addition of glucose.
Enzymatic Digestion with Trypsin
One mg of glycated HSA was dissolved in 1.3 mL of 50
mM NH4HCO3 buffer solution (pH 8.3) (Carlo Erba
Reagenti). After the addition of 15 L of a solution 45
mM of dithiothreitol (Fluka, St Louis, MO), the mixture
was heated at 50 °C for 15 min, then incubated with
trypsin (Sigma) (200 L of a solution 100 ng/L,
substrate to enzyme ratio  50:1 w/w) overnight at
37 °C. The reaction was stopped with 80 L of 10%
trifluoroacetic acid (TFA) (Fluka). Unglycated HSA was
treated in the same manner.
s of (
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0.5 mg of glycated HSA was dissolved in 50 L of 50
mM NH4HCO3 buffer solution (pH 8.3). After the
addition of 4.7 L of a solution 45 mM of dithiothreitol,
the mixture was heated at 50 °C for 15 min, then
incubated with Lys-C (Sigma) (50 L of a solution 150
ng/L, substrate to enzyme ratio  66:1 w/w) over-
night at 37 °C. The reaction was stopped with 5 L of
10% TFA. Unglycated HSA was treated in the same
manner.
HPLC
The tryptic digests were diluted 1:1 with 50% acetoni-
trile solution containing 0.1% TFA, and 40 L of the
sample solution was injected into a Jupiter C18 reverse-
phase column, particle size 5 m, 250  2 mm i.d.
(Phenomenex, Torrance, CA). Solvent A consisted of
water with 0.1% TFA and Solvent B of acetonitrile
(Carlo Erba Reagenti) containing 0.1% TFA. The gradi-
ent profile for Solvent B was as follows: 15%, 1 min;
15–45% in 33 min; 45%, 5 min; 45–95% in 10 min; 95%,
15 min. The flow rate was 0.2 mL/min.
After elution from the column, the samples were
analyzed by a diode array detector (1100 Series, Agilent
Technologies, Palo Alto, CA) and then ionized by the
ESI source of the mass spectrometer (see below). The
Lys-C digests were diluted 1:10 with 50% acetonitrile
solution containing 0.1% TFA and analyzed in the same
manner.
ESI/MS
ESI/MS was performed on a Agilent 1100 LC/MSD
Trap (Agilent Technologies) operating in positive ion
mode. Instrumental parameters were: Nebulizer pres-
Figure 1. MALDI spectra of tryptic digestsure 40 psi, auxiliary gas flow 10 mL/min, temperature
of auxiliary gas 325 °C, capillary voltage 4 kV, exit
capillary voltage 50 V, skimmer voltage 30 V. MS and
MS/MS analyses were performed for every sample,
favoring fragmentation of doubly charged ions.
MALDI/MS Measurements
MALDI mass measurements were performed on a Voy-
ager-DE PRO instrument (Applied Biosystems, Foster
City, CA), operating in reflectron positive ion mode.
Ions formed by a pulsed UV laser beam (nitrogen laser,
  337 nm) were accelerated to 20 keV. Delayed
extraction (DE) conditions were: Accelerating voltage
20 kV; grid voltage 76%; guide wire 0.002%; delay time
175 ns. -cyano-4-hydroxycinnamic acid (Sigma) was
used as matrix (10 mg/mL in H2O/acetonitrile 1/1
vol:vol). The digestion mixtures were diluted ten times
with 0.1% trifluoroacetic acid aqueous solution, and 5
mL of this solution were added to the same volume of
the matrix solution. About 1 mL of the resulting mixture
was deposited on the stainless steel sample holder and
allowed to dry before introduction into the mass spec-
trometer. Three independent measurements were taken
for each sample. External mass calibration was applied
using the Calibration Mixture 2 of Sequazyme Peptide
Mass Standards Kit (Applied Biosystems), based on the
monoisotopic values of [M  H] of Angiotensin I,
ACTH (1-17 clip), ACTH (18-39 clip), ACTH (7-38 clip)
and bovine insulin at m/z 1296.68, 2093.09, 2465.20,
3657.93, and 5730.61 respectively.
Computer-Molecular Modeling
The entire HSA was built by computer-molecular mod-
eling starting from the Protein Brookhaven Database
a) unglycated HSA and (b) glycated HSA.
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ton, NY).
All modeling was carried out using SYBYL and
BIOPOLYMER modules of commercial software (Tri-
pos, St. Louis, MO). The solvent accessible surfaces
(SAS) of the amino acids making up the structure of
HSA were calculated using the Xsight module of MSI
software (MSI, San Diego, CA).
Results and Discussion
The present study is the logical evolution of previous
studies devoted to identifying glycated peptides origi-
nating from enzymatic digestion of in vitro glycated
HSA with proteinase K [11] and trypsin [12]. In princi-
ple, it would lead to the structural identification of AGE
peptides whose presence, in further researches, will be
verified in plasma samples of healthy, diabetic, and
end-stage renal failure subjects.
We are well aware of the very different protein
degradation mechanisms in in vitro experiments and in
physiological conditions but, considering all the gly-
cated peptides identified in the present and in the
previous two investigations, we hope to obtain some
interesting results, to be transposed in in vivo studies.
The general strategy employed in the present study
may be summarized as follows: Unglycated and in vitro
glycated HSA were digested by trypsin and Lys-C.
Digestion was without any derivatization of the sulfhy-
dryl groups, to remain as close as possible to the
conditions present at a systemic level. The glycation
Figure 2. Total ion current (TIC) chromatogra
glycated HSA.level of the glycated protein was determined by MALDI
measurements, yielding the total number of glucose
molecules condensed on the protein. The digestion
mixtures of both unglycated and glycated HSA were
analyzed both by MALDI, to obtain their “fingerprints”,
and by LC with various detection systems: UV (214 and
280 nm, effective for detection of peptides) and ESI/MS,
performed by ion trap. The latter approach was applied
to further MSn experiments. The experimental data
were rationalized by comparison with databases and
theoretical data from molecular modeling.
HSA was incubated with 0.5 M glucose in sterile
conditions for 28 days. The reason for choosing this
high glucose concentration, quite far from physiopatho-
logical values (20–50 mM) was to enhance the yield of
glycation processes. The MALDI spectrum of the result-
ing sample showed a wide peak due to protonated
molecules centered at m/z 68921, whereas the spectrum
of unglycated HSA detected MH species at m/z 66645
(material available on request). Comparison of the two
spectra showed that the glycated HSA sample is a
mixture of proteins with different glycation levels, as
proven by the broad shape of the peak; the mass value
given above must be considered the mean. As the
condensation of one glucose molecule leads to a mass
increase of 162 Da, the mean m/z value corresponds to
proteins containing 14 glucose units. However, it must
be taken into account that, considering the half-height
peak width, the number of glucose molecules con-
densed on the protein ranges from 1 to 29.
Glycated and unglycated HSA were digested by
f tryptic digests of (a) unglycated HSA and (b)ms o
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r.t
(min) [M  H] ESI Charge state Sequence [M  H] MALDI*
6.9 1518.7a 1, 2 182-195
7.1 1074.5a 1, 2 182-190
8.9 880.4 1, 2 226-233
9.6 875.3 1, 2 219-225 875.3
11.5 1022.4 1, 2 476-484 1022.6
11.7 1296.4a 2 349-359
12.2 789.4 1, 2 234-240
13.4 1318.5 1, 2 82-93
13.5 673.3 1, 2 213-218 673.6
15.3 1189.6 1, 2 277-386
17.2 1226.7 1, 2 11-20
17.4 1430.8 1, 2 275-286
18.5 1252.4 2 223-233
18.7 1055.5 1, 2 137-144
18.9 927.5 1, 2 138-144 927.5
19.1 1149.9 1, 2 42-51 1149.7
19.4 1737.6a 2 219-233
19.7 1016.9a 1 65-73
20.0 1640.1 1, 2 414-428
20.5 1019.4 1, 2 210-218 1019.7
20.8 960.4 1, 2 403-410 960.8
21.1 1128.7 1, 2 525-534
21.2 3244.9 3 546-574
21.9 2381.2 2, 3 198-218
22.2
1001.6 1, 2 526-534
1013.9 1, 2,
Na
575-585
23.0 2413.8 2, 3 241-262 2414.0
24.6 1854.1 2 485-500 1853.3
25.5 3184.6 2, 3 234-262
25.9
1600.6 1, 2 390-402
983.7 1 352-359
27.7 3239.4a 2, 3 52-81 3239.0
27.9 2488.8 2, 3 501-521 2488.0
28.0
2045.2 2, 3 373-389 2046.1
1342.8 1, 2 546-557
28.5 1468.0 1, 2 337-348 1467-8
29.0 1311.7 1, 2 338-348 1312.2
29.5 2722.4 2, 3 115-137 2721.2
29.8 2935.0 2, 3 137-159
31.8 2543.2 2, 3 390-410 2543.0
32.1 3543.2 2, 3 445-475 3542.0
32.2 2918.4 2, 3 287-313
32.4 1651.7 1, 2 226-240
32.5 3362.6 3 287-317
32.6 3215.4 2, 3 445-472 3213.0
33.2 2559.2 2, 3 445-466 2559.2
33.5
3058.4 2, 3 446-472 3057.3
2055.6 2, 3 145-160 2056.1
33.9 1639.7 1, 2 324-336 1Met-ox 1639.5
34.1 1898.9a 1, 2 145-159 1899.0
34.2 2403.0 2 446-466
34.4 746.4 1 21-27
35.3 1898.9 1, 2 146-160 1899.0
36.1 1742.8 1, 2 146-159 1742.5
36.3 2301.0 2, 3 318-336 2301.2
37.6 1623.9 1, 2 324-336 1623.8
aPeptides present only in the digestion products of unglycated HSA.
*Further ionic species were detected in MALDI conditions only: 1083.8 (sequence 138-145), 1502.6 (sequence 210-222), 1699.5 (sequence 429-444),
3385.6 (sequence 403-432), 1779.8a (sequence 324-337), 1875.0a (sequence 65-81).
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mental section). In view of the complexity and high
number of results, the data relating to the two types of
enzymatic digestion are described and discussed sepa-
rately, and compared in the Conclusion section.
Digestion by Trypsin
The MALDI spectra of the tryptic digests of unglycated
and glycated HSA are shown in Figure 1, comparison of
which clearly reveals differences between the two. At
first sight, the most evident result is the complete
disappearance of ionic species at m/z 1899.0 (which, in
the case of the sample from unglycated HSA, represents
the most abundant one) and 2056.1 in the glycated HSA
digest. Some other peptides remain present in both
mixtures, e.g., those at m/z 1467.8 and 1623.8. However,
the MALDI spectra of Figure 1b show few new species,
generally of low abundance, in the digestion mixture
from glycated HSA. This is the case of the ions at m/z
1179.6, 1405.7, 1700.9, 2165.1, and 2413.0.
These results may appear at first sight disappointing,
since a larger difference would have been expected.
However, they are very similar to those obtained in
previous studies which indicate a lower proclivity to-
Table 2. Protonated ions of trypsin digestion products presente
MALDI data
r.t. (min) [M  H] ESI Charge state [M  H]
11.5 1458.7 1, 2
13.5 1512.4 2
17.0 1592.7 1, 2
19.0 1179.5 1, 2 1179
20.6 1290.7 1, 2
21.6 2542.6 2, 3
24.3 3940.0 3
25.2 1578.6 1, 2 1579
25.5 1056.5 1, 2
26.3 894.4 1, 2
27.0 1198.7 1, 2 1198
27.6 2207.6 2, 3
28.2 738.3 1, 2
29.7 1405.8 1, 2 1405
31.6 3523.9 3
32.1 1812.9 1, 2
32.4 2003.0 2
33.1 2303.8 2
1396.5 1, 2
35.5 2462.8 2, 3 3462
2185.8 2, 3
39.3 2164.2 2 2165
Scward digestion for glycated protein. This aspect was
also considered, not only in in vitro experiments but
also cited as the rationale for some results obtained in
physiological conditions. Both works by Schnider and
Kohn [14] and Vlassara et al. [2] relate this aspect with
the solubility of collagen from human skin, tracheal
cartilage and dura mater and, more generally, with its
implications for diabetes and aging.
The same tryptic digests were analyzed by LC. In the
case of the unglycated HSA digest, UV detection at 214
nm (material available on request) revealed its high
complexity: Some peaks detected here disappeared in
the sample from glycated HSA and in the latter case,
new species became detectable. Similar results were
obtained with UV detection at 280 nm (material avail-
able on request), further confirming that glycated HSA
is less prone to enzymatic digestion. Passing to LC/
ESI/MS experiments, the total ion chromatograms (Fig-
ure 2) confirm the UV data (cfr. chromatograms of
digestion products from unglycated HSA, Figure 2a,
with those from glycated HSA, Figure 2b). These chro-
matograms are the starting point of an extensive inves-
tigation devoted to identifying the various peptides
produced by enzymatic digestion.
y in glycated HSA detected in ESI spectra and compared with
DI
Sequence
( mass increase) Modified amminoacid
349-359 (162) 351K
275-286 (162) 276K
525-534 (162) 525K
198-218 (162) 199K or 205K or 209R or 212K
440-472 (162) 444K or 445R or 466K
187-199 (162) 190K or 195K or 197R
137-144 (144) 137K
373-389 (162) 378K
287-317 (162) 313K
226-240 (162) 233K
542-557 (162) 545K
539-557 (162) 541K or 545K
223-233 (144) 225K
318-336 (162) 323K
223-240 (162) 225K
1d onl
MAL
.0
.6
.7
.2
.1heme
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tryptic digests are listed in Tables 1 and 2. The ESI and
MALDI data for the digest of unglycated HSA are
shown in Table 1. The sequences of Column 4 were
obtained by comparing the mass values of the various
peptides with those calculated by the protein digestion
Figure 3. MS/MS spectrum of doubly charged
cated (m/z 826.0) and (b) containing a glucose m
Figure 4. MALDI mass spectra of Lys-C digetool MS-Digest (ProteinProspector version 4.0.5). It
must be emphasized that the comparison of LC/
ESI/MS and MALDI data (Table 1) indicates that the
former approach is the more effective, since only 27 of
the 56 peptides detected by LC/ESI/MS also occur in
the MALDI spectra. However, in MALDI conditions,
s corresponding to sequence 226-240 (a) ungly-
ule condensed on 233K (m/z 907.3).
f: (a) Unglycated HSA and (b) glycated HSA.ion
olecsts o
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identified and are reported in the note to Table 1. For an
idea on the validity of these results, it must be stressed
that the identified peptides cover 78% of the whole
protein.
Data pertaining to the tryptic digest of glycated HSA
show the presence of most of the peptides detected in
the case of the unglycated HSA digest, although in
lower abundance. However, as expected, a series of
new peptides (some glycated, some others, as discussed
below, originating from a different enzymatic action)
occur; for easier discussion of the data, only peptides
characteristic of glycated HSA are listed in Table 2.
These possibly glycated peptides show mass values
ranging from 738.3 to 3940.0 Da. In principle, they
originate from portions of HSA in which glucose mol-
ecule(s) have condensed, with and without further
dehydration processes. For example, the peptide de-
tected at a retention time of 27.0 min shows a mass
value of 1198.7, corresponding to the sequence 137-144,
in which the dehydrated glucose molecule has con-
densed on 137K. Interestingly, the unglycated peptide
with the same sequence is present in the digestion
mixture of unglycated HSA at m/z 1055.5 (r.t.  18.7
min).
However, it should be emphasized that profound
changes occur in enzyme action, as evidenced by the
data of Table 2. First of all, some enzymatic cleavages,
never observed in the case of unglycated HSA, become
operative, proving that glycation strongly modifies en-
zyme action. For example, the peak eluting at 17 min is
due to the glycated peptide with sequence 275-286; the
Figure 5. Total ion current (TIC) chromatogram
HSA.same sequence, obviously not glycated, is completely
absent in the case of unglycated HSA. A further exam-
ple is shown by the data relating to the sequence of in
Scheme 1. The portion 181-200 of unglycated HSA
undergoes different cleavage when glycated. Thus, the
left side of Scheme 1 shows that the unglycated se-
quence is enzymatically cleaved at 181K, 195K, and 197R,
whereas in the case of glycation (in either 190K or 195K),
cleavages occur at 186R and 197R.
As in the example above, assignment of the glycation
site cannot always be made on the basis of the peptide
mass value when it contains differing K residues. As
shown in Table 2, for some of these peptides no
sequences could be assigned.
As for the tryptic digest of unglycated HSA, a lower
number of characteristic peptides originating from the
tryptic digestion of glycated HSA were been detected
by MALDI/MS (Table 2).
The sequence data, first obtained by comparison
with databases, were investigated by MS/MS experi-
ments on doubly charged ions. In the case of peptides
from unglycated HSA, spectra analogous to that shown
in Figure 3a for the ion at m/z 826.0 (corresponding to
the sequence 226-240) were obtained, and the ions of the
y and b series are clearly evidenced.
In the case of peptides containing a glucose moiety,
completely different behavior was observed, as shown
in the MS/MS spectrum of the doubly charged ion at
m/z 907.3, corresponding to the sequence 226-240, with
a glucose molecule condensed on 233K (see Figure 3b).
In this case, only a highly favored water loss is ob-
served, and ions due to the y and b series are practically
ys-C digests of: (a) Unglycated and (b) glycateds of L
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dant y and b series ions identified the glycation sites
(e.g., 351K, 525K, 137K, 378K, 313K, 233K, 545K, 225K, and
323K; see Table 2). In other cases, identification of
glycation site(s) was impossible, due to the complete
lack of any specific y and b ions in the MS/MS spectra
of the related doubly charged ions (e.g., peptides at m/z
1578.6, 2303.8, 2542.6, and 3940.0; see Table 2). MS3
spectra from collisionally generated [M  H2O]
2 spe-
cies show very few product ions still related to the
glucose moiety.
This behavior may be ascribed to the collision con-
ditions in the ion trap experiments: the low, step-by-
step energy deposition, typical of the device [15],
greatly favors low critical energy decomposition chan-
nels, and the water loss, being a process requiring H
rearrangement, is certainly more energetically favored
than single bond cleavage.
However, what at first sight may be viewed as a
negative aspect is really a highly efficient diagnostic
tool in identifying glucose-containing peptides among
Table 3. Protonated ions of Lys-C digestion products common
conditions
r.t. [M  H] ESI Charge st
6.8 973.7 1, 2
6.0-6.8 1379.7 1, 2
8.3 1386.7 1, 2
9.2 880.6 1, 2
12.2 789.7 1, 2
12.4 951.7 1, 2
12.9 854.7 1
13.6 1255.6 1, 2
14.8 1189.9 1, 2
16.3 1627.9 1, 2
18.7 1149.8 1, 2
20.6 1128.9 1, 2
21.2 1017.9 1, 2
21.5 2414.0 2, 3
21.8
1353.0 1, 2
1001.0 1, 2
21.9 1013.9 1, 2, N
22.2 1141.9 1, 2
23.4 1530.0 1, 2, 3
23.7 2053.4 2, 3
24.0 1771.0 1, 2
24.1 1924.1 1, 2
25.2 2858.6 2, 3
25.3 2393.8a 2, 3
25.6
1600.9 1, 2
983.8 1
26.8 2176.4 2, 3
27.5 2046.6 2, 3
27.6 1342.9 1, 2
28.0 2203.0 2, 3
31.7 2918.8 2, 3
32.4 2559.8 2, 3
34.0 746.5 1
34.8 2937.0 2, 3
35.8 2809.8 2, 3
37.4 4064.2 3, 4
aPeptides present only in the digestion products of unglycated HSA.the digestion products of glycated HSA. This point is
more easily evaluated by the following general consid-
eration: Digestion of glycated HSA leads to some pep-
tides which are also produced in the case of unglycated
protein and to new peptides, some of them glucose-
containing and some not, due to different enzyme
activity. In the case of the present study, devoted to the
structure identification of possible AGE-peptides, dis-
crimination between the two sets of compounds is
essential, and MS/MS experiments are highly effective
in this respect.
Digestion by Lys-C
Lys-C is a serine protease and, at pH 8.3, specifically
cleaves peptide bonds C-terminally at lysine [16]. After
the action of this enzyme, unglycated and glycated HSA
give the MALDI mass spectra of Figure 4a and b
respectively. As in the case of trypsin digestion, some of
the species originating from the unglycated protein can
no longer be detected in the spectrum of digestion
glycated and glycated HSA, detected in both ESI and MALDI
Sequence [M  H] MALDI
5-12 973.5
360-372
263-274
226-233
234-240
13-20
206-212 854.5
163-174 1255.5
277-286
263-276 1627.8
42-51 1149.6
525-534
65-73 1017.5
241-262 2413.1
403-413 1352.8
526-534
575-585
565-574
213-225 1529.9
414-432 2053.2
175-190 1770.9
415-432
501-524 2859.3
213-233 2392.3
390-402 1600.7
352-359
542-560 2177.0
373-389 2046.1
546-557 1342.6
501-519 2203.0
287-313 2919.3
445-466 2559.3
21-27
137-159 2935.6
138-159 2808.5
318-351to un
ate
a
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become detectable, among which some AGE peptides
must necessarily be present. These differences are fur-
ther evidenced by the LC run of the two digestion
mixtures. UV detection (214 nm; material available on
request) highlighted a large number of glycated pep-
tides in the retention time range 36-43 min, leading to a
broad chromatographic peak. These species must be
highly absorbing compounds, since the same behavior
is not observed in the LC/MS run (Figure 5b), in which
components differing from those in the unglycated
HSA digestion mixture are present, but with compara-
ble abundances.
Analysis of the LC/ESI/MS data with the same
methods employed in the case of trypsin digestion are
reported in Tables 3 and 4. Table 3 shows that most of
the peptides originating from Lys-C digestion of ung-
lycated HSA are species already detected in the tryptic
digest (see Table 1). In this case, the identified peptides
Table 4. Protonated ions of Lys-C digestion products present on
MALDI data
r.t.
(min)
[M  H]
ESI Charge state
[M  H]
MALDI
4.9 970.9 1
6.1 762.7 1,2 762.4
15.8 1866.4 2 1865.8
16.4 1594.2 2 1593.7
18.5 1069.9 1,2
19.1
1626.0 1,2 1625.9
1754.2 2,3 1754.0
19.6 2107.8 2,3
20.1 1291.0 1,2
20.5 2676.6 2,3
20.9 2544.4 2,3
23.0 2378.8 2,3 2378.2
23.8 786.8 1,2 787.5
23.9 1124.0 1,2 1123.6
24.3 804.7 1
24.6 2089.0 2,3 2088.0
24.9 1578.1 1,2 1577.7
26.9 3021.0 2,3 3020.4
27.4 2208.4 2
27.6 738.7 1,2
28.2 2558.4 2,3 2558.3
30.7 3284.0 2,3 3284.6
31.4 2200.2 2
31.6 1813.2 1,2,3
31.7 2315.0 2,3 2314.2
31.9 2004.4 2
33.8 1285.0 1,2 1284.7
34.5 3099.0 2,3
35.1 1346.1 1,2
35.5 1834.8 2 1832.9
37.0 3169.6 2,3 3170.8
39.1 1572.0 1,2 1571.9
39.4
2078.0 2
2596.6 2,3
39.5 1237.1 1,2
41.1 3728.2 3,4
41.6 4514.5 3,4,5
42.7 3080.0 2cover 70% of the whole protein. Only a few of them are
specifically produced by Lys-C. The HSA digestion data
obtained from trypsin and Lys-C are compared in
Figure 6: The green color code represents the protein
portion whose related peptides were identified with
both enzymes; blue indicates peptides only identified in
digestion by Lys-C; yellow shows digestion products
for trypsin only.
The enzyme activity of Lys-C on glycated HSA is
very different from that observed for trypsin. As shown
in Table 4, in which only peptides specific for digestion
of glycated HSA are listed, a high number of peptides
are generated (54; in the case of trypsin digestion, only
22 were detected). At first sight, these results are
surprising; the higher specificity of Lys-C (which
cleaves at K residues) versus trypsin (which cleaves at
both K and R residues) would, in principle, lead to less
extensive protein degradation. The above results may
be explained by the considerable modifications occur-
glycated HSA, detected in ESI spectra and compared with
Sequence
( mass increase) Modified amminoacid
535-541 (162) 536K
160-174 (162) 162K
275-286 (162) 276K
403-414 (144) 413K
414-429 Not glycated (cleavage at 429N)
525-534 (162) 525K
42-64 (162) 51K
198-218 (162) 199K or 205K or 209K or 212K
175-195 (162) 181K or 190K
Not glycated
403-411 Not glycated (cleavage at 411Y)
275-286 (144)
373-389 (162) 378K
241-262 (144) 257R or 262K
440-466 (162) 444K
226-240 (162) 233K
542-557 (162)545K
565-574 (144) 573K
149-159 Not glycated (cleavage at 148Y)
324-359 (162) 351Kly in
I/LC
506 LAPOLLA ET AL. J Am Soc Mass Spectrom 2004, 15, 496–509ring in lysine residues after glycation, which reflects
different enzyme activity.
The sequences identified in the Lys-C digest of
glycated HSA are listed in Table 4, and it is interesting
to note that some of identified peptides have already
been detected in the case of trypsin digestion. On the
basis of the specific behavior described above, MS/MS
experiments are effective in discriminating between
glucose-containing and unglycated peptides. These
experiments yielded some unexpected data regarding
production of peptides at m/z 1124.0, 1346.1 and
1754.2. The first two species were identified as attrib-
utable to sequences 403-411 and 149-159 respectively,
both originating from a cleavage at C-terminal Y
residues, which have never been described as the
Figure 6. Peptides identified by ES
Figure 7. Glycated peptides identifiedcleavage site of Lys-C. The last one (at m/z 1754.2)
originates from the cleavage at C-terminal N residue,
a process already described in the literature [17] as
unexpectedly activated by Lys-C and, in this partic-
ular case, present only in the digest of glycated HSA.
The occurrence of these enzymatic cleavages is ex-
plained by modification of typical cleavage sites, due
to glycation.
Comparisons Between Trypsin and Lys-C
Digestion Data
The above results show that enzymatic digestion of
glycated HSA by trypsin and Lys-C leads to a high
/MS analyses of unglycated HSA.
SI/LC/MS analyses of glycated HSA.by E
507J Am Soc Mass Spectrom 2004, 15, 496–509 MS STUDIES ON AGE/PEPTIDESnumber of peptides, some of which are already
present in the digestion mixture of unglycated HSA
(and consequently not glycated species), whereas
others are specific for the glycated protein. In the
latter case, a further distinction must be made be-
tween glycated and unglycated peptides: the latter
Figure 8. Most solvent-exposed lysine residues, color-coded ac-
cording to their range of fractional solvent accessible surfaces (red:
0.5–1.0, most exposed; yellow: 0.3–0.5, less exposed; green: 0.1–
0.3, buried).
Table 5. Glycated K residues formed in the digestion of glycate
accessible surface values
Glycated
residue
[M  H] of the peptide
containing the glycated
residue in the
tryptic digest
[M
co
313K 3523.9
233K 1812.9
573K
51K
276K 1592.7
444
378K 2207.6
225K 1396.5; 2185.8
323K 2462.8
351K 1458.7
137K 1198.7
536K
162K
545K 2003.0
525K 1290.7
413K
aColor code: Red  more exposed: 0.5–1.0; Yellow  less exposed: 0.3are due to different enzymatic cleavages of the gly-
cated protein.
In order to identify possible AGE peptides generated
by enzymatic digestion of glycated HSA, the data from
the digestion mixtures of these substrates with the two
different enzymes were compared, to highlight analo-
gies and differences.
A description of these data is given on the basis of
HSA sequence. Peptide mapping of glycated peptides
identified in the digestion mixtures of glycated HSA
only is shown in Figure 7. The same color codes as
Figure 6 were employed. First of all, note that not all the
K-sites have been glycated. In fact, the glycated pep-
tides identified by both MALDI/MS and LC/ESI/MS
cover only 54% of the whole protein. This result may be
explained as due to two different phenomena: (1) A
different enzymatic action on the glycated protein,
which leads to preferential production of some glycated
peptides; (2) the occurrence of favored glycation pro-
cesses on specific lysine residues belonging to the
protein chain. The data of Figure 7 indicate that at least
16 lysine residues belonging to the protein chain reacted
with glucose, fitting the MALDI/MS measurements on
the intact glycated protein, showing a mean glycation
value of 14.
It should be emphasized that a series of peptides
are common to both enzymes and consequently may
be considered, in pectore, as possible AGE peptides.
Their mass value ranges from 1290 to 2208 Da, and
some of them were already identified in the previous
study performed by LC/FT-MS on glycated HSA
[12].
The glycation sites are, in most cases, clearly identi-
fied and are labeled in red in Figure 7. The experimental
data described above indicate that 233K, 276K, 378K, 545K,
A with trypsin and Lys-C and related fractional solvent
] of the peptide
ing the glycated
sidue in the
ys-C digest
Fractional
solvent
accessible
surface
0.881 Reda
1813.2 0.779 Reda
1285.0 0.777 Reda
2676.6 0.713 Reda
1594.2 0.645 Reda
3284.0 0.623 Reda
2208.4 0.610 Reda
0.565 Reda
0.535 Reda
4514.5 0.476 Yellowa
0.474 Yellowa
970.9 0.425 Yellowa
1866.4 0.417 Yellowa
2004.4 0.347 Yellowa
1291.0 0.337 Yellowa
1626.0 0.197 Greena
Green  buried: 0.1–0.3.d HS
 H
ntain
re
L
–0.5;
508 LAPOLLA ET AL. J Am Soc Mass Spectrom 2004, 15, 496–509and 525K are privileged glycation sites. To obtail further
support to these results, a molecular modeling study
was undertaken in order to identify the most exposed
lysine residues, necessarily more available to possible
glycation processes.
The structure of HSA is shown in Figure 8, in which
the different lysine residues are evidenced and color-
coded with respect to SAS values. These theoretical
values are compared with the experimental ones in
Table 5, showing generally good agreement between
the two findings, as most of the identified glycation
sites are sufficiently exposed to be prone to react with
glucose. However, some discrepancies appear, e.g.,
those related to glycated residues 545K, 525K, and 413K,
which are detected even though their SAS values are
particularly low. This result may be due to an at least
partial tertiary structural modification of the protein,
induced by glycation and/or by acid catalysis [18].
At this point, it becomes interesting to compare our
data with those from previous researches on in vivo
glycated sites of HSA. Garlick and Mazer [18] showed
that the predominant glycation site of HSA in vivo is
525K, whereas in vitro incubation of HSA with glucose
[19] indicates that a different amino acid, 199K, is
glycated. Later, this result was partially confirmed by
Iberg and Fluckiger [20], who determined that in vivo
glycated HSA shows that glucose condenses on 199K,
281K, 439K, and 525K. Evidence for the assignment of five
other sites was less certain, but consistent with glyca-
tion at 233K, 317K, 351K, 12K and 534K. However, it was
shown that approximately 33% of total glycation occurs
at 525K.
In our case, the high glucose concentration employed
for HSA incubation leads to more extensive glycation of
the protein, reflecting the production, by enzymatic
digestion, of a higher number of glycated peptides. It is
worth noting that some of the glycation sites observed
in the present study are the same as those determined in
in vivo experiments, and consequently indicate that the
presence of AGE peptides containing those lysine resi-
dues is to be expected.
Conclusion
In conclusion, among the trypsin and Lys-C enzy-
matic digestion products, the present study identified
some glycated peptides, some of which are common
to the two digestion mixtures. Molecular modeling
and experimental data are mostly in agreement, in-
dicating that these glycated peptides contains lysine
residues exhibiting high solvent accessible surface
values.
In our opinion, these data are a good starting point to
investigate the presence of these peptides in human
plasma from healthy, diabetic and nephropathic sub-
jects, in order to confirm their nature as AGE peptides.References
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